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ErbB2 and EGFR are attractive oncology therapeutic targets as their overexpression in tumors predicts a poorer clinical outcome in a
variety of epithelial malignancies. However, clinical results with therapeutic compounds targeting these receptors have been mixed.
Therefore, there is a need for improved predictive biomarkers for these targeted therapeutics. In this study we analysed tissue
microarrays of patients treated with combination chemotherapy and Herceptin for expression or phosphorylation of signalling
proteins associated with erbB receptors to identify protein biomarkers that are predictive of breast cancer patient response. A
comparison of expression or phosphorylation of these markers with patient outcome revealed that response to Herceptin depended
not only on expression levels of erbB2 but also on expression of EGFR, expression of erbB ligands, expression of other receptors and
phosphorylation of downstream proteins. Elucidating the biological effects of EGFR/erbB2 targeted therapeutics will enable patient
tumor profiling to identify likely responders and the determination of biologically effective doses that allows chronic administration of
these agents in order to maximise efficacy.
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The erbB family of receptors, namely EGFR and ErbB2, are
important drug targets for cancer therapeutics and are the focus of
a large number of current clinical trials. In addition, one of the first
approved targeted cancer therapeutics was Herceptin, an antibody
inhibitor of ErbB2. The successful clinical development of
Herceptin depended upon the selection of patients based upon
the overexpression of ErbB2. However, the response rate for
Herceptin in breast cancer, when used in combination with
chemotherapy, was approximately 50% in the pivotal clinical trial
(Hortobagyi, 2001). Importantly, this response rate is observed in
patients that are overexpressing ErbB2. Based upon these response
rates, it is clear that better predictive markers are needed to select
patients for treatment with Herceptin or other erbB inhibitors.
The response rate observed with erbB inhibitors in patients
selected solely on the basis of the overexpression of a single erbB
receptor is not unexpected given the complexity of erbB signalling.
Most tumors of epithelial origin express multiple erbB (HER)
receptors and co-express one or more EGF-related ligands,
suggesting that autocrine receptor activation plays a role in tumor
cellular proliferation. As these ligands activate different erbB
receptors, it is possible that multiple erbB receptor combinations
might be active in a tumor, a characteristic that could influence its
response to an erbB-targeted therapeutic (Karunagaran et al,
1996). The ligands present may select the dimerization partners,
and may also influence the time course of membrane transloca-
tion, activation and internalization of the receptor (Peles et al,
1993; Tzahar et al, 1994; Pinkas-Kramarski et al, 1996). Down-
stream signalling may be determined by the set of docking proteins
that may bind to the activated receptors. For example, erbB3
contains six major docking sites for phosphoinositide-3-kinase
(PI3K). NDF/Heregulin ligand stimulation of erbB receptors causes
activation of the PI3K pathway and phosphorylation of AKT
(Altiok et al, 1999; Liu et al, 1999; Xing et al, 2000). These
observations implicate PI3K/AKT in the signalling cascade that
results from erbB3 heterodimerisation with overexpressed ErbB2
in breast cancer cells. Importantly, activation of PI3K/AKT
promotes cell survival and enhanced tumor aggressiveness (Bacus
et al, 2002) and inhibition of the AKT pathway may be required
for Herceptin effect (Yakes et al, 2002). Recent results have
suggested that erbB receptors may be transactivated by other
receptor classes such as G protein coupled receptors, cytokine
receptors and insulin-like growth factor receptor (IGF-IR)
(Gschwind et al, 2001).
To address the need for predictive biomarkers for Herceptin
response in breast cancer patients, we analysed breast cancer tissue
sections taken from patients treated with Herceptin and
chemotherapy by immunohistochemistry (IHC) for expression of
erbB ligands and receptors and phosphorylation of downstream
signalling proteins. For this analysis we used tissue microarrays of
the samples. Tissue microarrays are a well-validated method to
rapidly screen multiple tissue samples under uniform staining and
Received 29 December 2003; revised 28 June 2004; accepted 29 June
2004; published online 10 August 2004
*Correspondence: SS Bacus; Email: sbacus@tmdlab.com
British Journal of Cancer (2004) 91, 1190–1194
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sscoring conditions (Hoos et al, 2001). The results of the analysis
identify a set of biomarkers that best predict patient outcome
following Herceptin combination therapies. Patient probability of
response ranging from 0 to 100% was observed based upon the
expression or phosphorylation of a small set of ligands, receptors
and signalling proteins.
MATERIALS AND METHODS
Tissue micro-arrays of 250 metastatic breast cancer patients who
received first-line chemotherapy together with Herceptin were
obtained from Clinomics Biosciences (Pittsfield, MA, USA). All of
the tissues were obtained under institutional IRB approval. The
histology of the tumors varied with infiltrating ductal carcinoma
being most common. All patients received radiotherapy post-
surgery. The tissue samples in the array were taken before
treatment and were all taken from the primary tumor unless
otherwise noted. ErbB2 expression had been determined by the
Herceptest on the original biopsies for all patients. Patient
response was based upon the case histories at last follow-up as
decided by the independent investigators for the clinical trials
from which the samples were obtained. Patients who were free of
disease at the time of examination after therapy were classified
as disease free. Patients whose tumors had not progressed at the
time of examination were classified as having stable disease.
Patients who were disease free or had stable disease were grouped
together as nonprogressors. Patients who redeveloped the disease
after therapy or whose tumors progressed were classified as
progressors.
EGFR and erbB2 immunostaining was performed by using the
prediluted EGFR and erbB2 antibodies from Ventana Medical
Instruments, Inc. (VMSI, Tucson, AZ, USA). erbB3 (1:10) and
Heregulin (1:25) antibodies were obtained from NeoMarkers
(Fremont, CA, USA). TGF-a and IGF-IR antibodies were obtained
from Oncogene Sciences (San Diego, CA, USA) and NeoMarkers
(Fremont, CA, USA), respectively. EGFR, ErbB2, erbB3, IGF-IR,
Heregulin and TGF-a were immunostained using the ‘BenchMark’
(VMSI) with I-VIEW (VMSI) detection chemistry. Phospho-
specific HER2 (p-HER2, Y1248), phospho-specific ERK (p-ERK),
phospho-AKT (p-AKT) and phospho-S6 ribosomal protein
(p-S6) antibodies were obtained from Cell Signalling Technology
(Beverly, MA, USA), and immunostained using a labelled strepta-
vidin peroxidase technique. Slides for p-S6 ribosomal protein,
p-ERK and p-AKT were processed with antigen retrieval using
0.1M citrate buffer, pH 6.0 in the ‘decloaker’ (Biocare Corp.) and
the sections incubated overnight with the primary antibodies
at 41C. The next day, the slides were placed onto the Autostainer
(Dako Corp.) and the ‘LSAB2 kit (Dako) was used as the detec-
tion chemistry. DAB (Dako) was used as the chromagen. Slides
for p-HER2 were processed with antigen retrieval using 1mM
EDTA, pH 8.0 solution and processed manually using the Vector
Elite detection system. After immunostaining, all slides were
counterstained manually with 4% ethyl green (Sigma). ErbB2,
EGFR, erbB3, IGF-IR, TGF-a, Heregulin, p-ERK, p-AKT and
p-S6 ribosomal protein or phosphorylation levels were quantified
using alkaline phosphatase or peroxidase techniques and micro-
scope-based image analysis of immunohistochemical stained
slides (Bacus et al, 1997). Quantification was by means of a
CAS 200 image analyser, as previously described (Bacus and
Ruby, 1993). Slides for p-HER2 were scored manually following
the criteria of the Herceptest. For the purpose of the analysis,
tumors were classified as negative or positive for all antibodies
based upon the level of staining. Statistical analysis was performed
to quantify frequencies and calculate Pearson w
2 tests of signi-
ficance for interactions between variables. Comparisons were
performed only on samples for which all relevant data was
available.
RESULTS
Analysis of breast cancer tissue arrays
From the original tissue array of 250 patients, A total of 75 samples
were not used in this analysis for lack of clinical data or because
the sections did not contain tumor tissue. Of the remaining 175
patients, 28 samples lacked Herceptest results and were also
excluded from further analysis. In total, 70 patients were removed
from the analysis because of low ErbB2 expression (see below). Of
the remaining 77 patients, 73 were taken from the primary tumor,
three from lymph nodes and one from an adrenal metastases. The
demographics of these patients are presented in Table 1. The great
majority of patients had infiltrating ductal carcinomas and
received anthracycline plus cyclophosphamide. All patients had
4mg/kg Herceptin loading dosage and 2mg/kg weekly mainte-
nance dosage. Overall, 15% of the patients were disease free or had
stable disease while 85% had re-occurrence or progression of
disease as determined at the last examination.
ErbB2 expression levels were also analysed using the arrays
(results not shown) and compared to the reported Herceptest
results. Our results obtained with the arrays were very similar to
the Herceptest results. Therefore, in this analysis we used the
Herceptest results obtained from the original sections. In total, 70
patients had 2þ or less staining intensity whereas 77 had þ3
ErbB2 staining (these patients had been given Herceptin based
upon a serum assay for ErbB2 expression). As expected, we
observed ErbB2 expression strongly correlated with patient
response; 100% of the 0 or 1þ ErbB2 patients progressed while
only 77% of the 3þ patients progressed. This response rate is
lower than what has been reported previously (Baselga, 2002).
Based upon these results, we concentrated our analysis of
biomarkers on patients that expressed erbB2 at the highest or
þ3 level, as these are the patients most likely to respond to
Herceptin.
The 77 patients who overexpressed ErbB2 at the 3þ level were
analysed for expression levels of p-HER2, EGFR, erbB3, IGF-IR,
NDF/Heregulin, and TGF-a as well as activated downstream signals
p-ERK and p-AKT (phosphorylated forms of ERK and AKT) and
the downstream signal, p-S6 (or phosphorylated S6 ribosomal
protein). Representative immunohistochemical results are pre-
sented in Figure 1.
Similar to ErbB2, EGFR expression significantly correlated
with patient outcome (Table 2). Among these Herceptin-treated
patients, the percentage of nonprogressing patients was 30%
for EGFR-positive patients and 9% for EGFR-negative patients
as compared to 23% for the total group of patients. erbB3 is
thought to play an important role in downstream erbB signalling
in that is has PI-3-Kinase docking sites and forms active
Table 1 Demographics of breast cancer patient samples used in final
analysis of tissue microarray
Number of patients
Patients included in final analysis 77
Pathology
Infiltrating ductal carcinoma 65
Lobular carcinoma 3
Medullary carcinoma 1
Metastatic breast carcinoma 4
Scirrhous carcinoma 2
Treatment (plus Herceptin)
Anthracycline plus cyclophosphamide 63
Doxorubicin 14
Analysis on tissue array samples for which clinical and Herceptest data were available
and who overexpressed ErbB2.
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patients, 70 of them expressed erbB3. ErbB3 expression did not
significantly correlate with patient outcome, p-AKT level or
NDF expression although the low number of erbB3 negative
patients limits these comparisons in this data set. Interestingly,
p-HER2 was only observed in 22% of the patients. Of these, only
23% occurred in patients that were nonprogressors. The expres-
sion of other growth factor receptors may mediate patient
response as well, either through direct stimulation of downstream
pathways or through transactivation of the erbB receptors. We
observed high IGF-IR expression in approximately half of the
patients. IGF-IR expression alone did not correlate with patient
outcome.
We found expression of erbB ligands, including NDF and
TGF-a also varied among patients (Table 3). Approximately 70%
of the patients expressed high levels of NDF while approximately
57% expressed high levels of TGF-a. A significant correlation
was observed between NDF levels and patient outcome. A very
high proportion of NDF-negative patients progressed (91%)
whereas 62% of NDF-positive patients progressed compared
to a 70% progression rate in the total patient group. No predic-
tive relationship was observed between TGF-a levels and patient
outcome (Table 3). However, the combination of TGF-a or
NDF expression and EGFR overexpression did positively correlate
with patient outcome (data not shown; P¼0.02 and 0.03,
respectively).
The activation of heterodimers of erbB2 with erbB3 and EGFR
results in activation of the ERK and PI3K/AKT pathways.
Comparison of the levels of activated or phosphorylated ERK
alone failed to demonstrate any significant effect of elevated p-ERK
levels as a factor for patient outcome. Similarly, AKT activation
(p-AKT) or phosphorylation of S6 ribosomal protein alone, which
integrates multiple signals through mTOR and p70 S6 kinase, did
not significantly correlate with patient outcome.
To increase the predictive power of our analysis, we next
considered an analysis in which two or more of these biomarkers
were combined to characterise the tumor. In this analysis we found
that the combination of low EGFR expression and high ERK
activation significantly predicted a poor outcome (Table 4). A
comparison combining high EGFR and high p-AKT predicted a
poor patient outcome as well (18 vs 38% for patients with low
p-AKT levels). The combination of high EGFR and high NDF or
TGF-a expression predicted a better outcome compared to patients
that had low expression of EGFR and the ligand. For example,
while 39% of the patients with high EGFR and NDF expression
did not progress, all of the patients with low EGFR and NDF
expression progressed (Table 4) compared to 23% nonprogressors
in the total patient group.
Figure 1 Representative images of IHC results obtained from breast
cancer patient samples arrayed in a tissue microarray.
Table 2 Receptor tyrosine kinase expression vs patient outcome
Patient group n
%
Nonprogressors
%
Progressors
v
2 value/
P-value
EGFR positive 43 30 70 3.97/0.05
EGFR negative 23 9 91
Total 66 23 77
erbB3 positive 70 29 71 0.62/NS
erbB3 negative 7 43 57
Total 77 30 70
p-erbB2 positive 17 23 77 0.42/NS
p-erbB2 negative 60 32 68
Total 77 30 70
IGF-IR positive 33 24 76 1.93/NS
IGF-IR negative 35 40 60
Total 68 32 68
Analysis on tissue array samples for which clinical and Herceptest data were available
and who overexpressed ErbB2 at the 3+ level.
Table 3 Receptor tyrosine kinase ligand expression vs patient outcome
following therapy
Patient group n
%
Nonprogressors
%
Progressors
v
2 value/
P-value
NDF positive 55 39 62 6.35/0.02
NDF negative 22 9 91
Total 77 30 70
TGF-a positive 38 34 66 0.34/NS
TGF-a negative 29 28 72
Total 67 31 69
Analysis on tissue array samples for which clinical and Herceptest data were available
and who overexpressed ErbB2 at the 3+ level.
Table 4 Analysis of receptor and downstream protein activation or
ligand expression vs outcome in patients following therapy
Patient group n
%
Nonprogressors
%
Progressors
v
2 value/
P-value
EGFR pos/p-ERK pos 21 14 86 8.55/0.05
EGFR pos/p-ERK neg 19 42 58
EGFR neg/p-ERK pos 9 0 100
EGFR neg/p-ERK neg 14 14 86
Total 63 21 79
EGFR pos/p-AKT pos 17 18 82 6.96/NS
EGFR pos/p-AKT neg 26 38 62
EGFR neg/p-AKT pos 5 20 80
EGFR neg/p-AKT neg 18 6 94
Total 66 23 77
IGF-IR pos/p-S6 pos 13 8 92 10.54/0.02
IGF-IR pos/p-S6 neg 20 35 65
IGF-IR neg/p-S6 pos 12 67 33
IGF-IR neg/p-S6 neg 23 26 74
Total 68 32 68
EGFR pos/NDF pos 31 39 61 8.94/0.05
EGFR pos/NDF neg 12 8 92
EGFR neg/NDF pos 16 12 88
EGFR neg/NDF neg 7 0 100
Total 66 23 77
Analysis on tissue array samples for which clinical and Herceptest data were available
and who overexpressed ErbB2 at the 3+ level.
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ribosomal protein phosphorylation gave a favorable patient
response outcome (67% nonprogressors, Table 4). This compares
to patients with high IGF-IR expression and high S6 ribosomal
protein phosphorylation, 8% of who were nonprogressors. The
best combination of markers for the prediction of patient response
was NDF, IGF-IR and p-S6 (Table 5). All of the patients who had
high NDF expression, low IGF-IR expression and high S6
phosphorylation had stable disease or were disease free (however,
the number of patients in this category was only seven). In
comparison, all of the patients who had low NDF expression and
high IGF-IR expression progressed, regardless of S6 status
(Table 5). In patients with high NDF and EGFR expression levels,
phosphorylation of ERK correlated with a difference in progres-
sion from 28% (high p-ERK) to 54% (low p-ERK; Table 5).
Similarly, those patients with low levels of p-AKT with any other
combination of biomarkers that includes the expression of NDF,
did better than those that overexpress this protein (results not
shown). Taken together, our data show that ErbB2 together with its
ligand and other erbB receptors and ligands as well as other growth
factor receptors play a role in Herceptin response. Importantly,
analysis of a select combination of these proteins correlated with
progression rates that varied from 0 to 100%. Therefore, these data
suggest that the use of a defined set of markers may accurately
predict progression. For comparison, the ‘a priori’ level of predic-
tion of progression, without the use of these biomarkers, ranged
from 63 to 79%
DISCUSSION
The success of Herceptin therapies in the treatment of breast
cancer patients has been limited although those patients treated
overexpress the ErbB2 protein. Our results demonstrate that the
status of EGFR and the erbB ligands, NDF and TGF-a affect
Herceptin therapy response in breast cancer patients. Patients
whose tumors express high levels of EGFR, ErbB2 and NDF or
TGF-a are most likely to respond. Other studies that considered
cell lines in culture have shown that indeed not all tumor cells
respond to inhibition of ErbB receptors, despite exhibiting
aberrant EGFR and/or ErbB2 expression (Motoyama et al, 2002).
In this respect, it has been reported that a combination of the
EGFR-directed mAb C225 and the erbB2 directed mAb 4D5 or
using dual EGFR/HER2 inhibitors inhibited proliferation of tumor
cell lines more strongly than either mAb alone (Ye et al, 1999;
Motoyama et al, 2002; Xia et al, 2002). A diagnostic protocol for
predicting patient response to Herceptin and chemotherapy is
presented in Figure 2. The left arm of the protocol details the
analysis of the targeted pathways, namely the erbB receptors and
their ligands. The right arm of the protocol details the analysis of
alternative pathways, namely the IGF-IR pathway and downstream
signalling.
Our results suggest that the IGF-IR receptor may mediate
patient response to breast cancer therapies targeting ErbB2. High
IGF-IR expression combined with high S6 ribosomal protein
phosphorylation correlated with poor patient response regardless
of erbB expression indicating that IGF-IR was acting directly to
activate downstream signalling rather than through transactivation
of erbB receptors. IGF signalling in breast cancer has been shown
to occur through AKT activation (Dufourny et al, 1997; Oh et al,
2002), which would lead to S6 ribosomal protein phosphorylation.
Hence, S6 phosphorylation may indicate active IGF signalling in
those tumors overexpressing IGF-IR. A role for IGF-IR in patient
response has been suggested by cell line studies. Lu et al. (2001)
reported that Herceptin resistance could occur through activation
of IGF-IR. Other studies have indicated that co-targeting IGF-IR as
well as ErbB2 would produce synergistic inhibition of growth in
breast cancer cells (Camirand et al, 2002). Based upon our results
as well as the results of these published studies, analysis of IGF-IR
expression and downstream signalling may be critical for an
accurate assessment of potential Herceptin response in breast
cancer patients (right arm of Figure 2).
The percentage of patients that overexpress HER2 and also are
positive for p-HER2 in this study is similar to the percentage
observed by Thor et al, (2000). In addition, more of these patients
progressed than had stable disease or were disease free following
treatment. These observations clearly raise questions as to the
phosphorylation status of HER2 in tumor samples. The failure to
see more p-HER2 positive tumors and to see a correlation with
drug response may be due to rapid dephosphorylation of the
receptor in vivo or during tissue handling or inadequate sensitivity
of the antibody. However, cell line studies indicate that the p-HER2
antibody is capable of detecting HER2 phosphorylation following
ligand exposure (results not shown).
Our analysis of downstream signalling and patient response is
complicated by the inclusion of chemo- and radiotherapy in
addition to Herceptin for the patients analysed. AKT or MAP
kinase pathway activation, for example, is known to play a role
in response to DNA-damaging agents (Bacus et al, 2001; Clark
et al, 2002). Therefore, consideration of downstream signalling
Table 5 Analysis of ligand and receptor expression and downstream
protein activation vs patient outcome in patients following therapy
Patient group n
%
Nonprogressors
%
Progressors
v
2 value/
P-value
NDF neg/p-S6 pos/IGF-IR neg 2 50 50 19.41/0.01
NDF neg/p-S6 neg/IGF-IR neg 9 11 89
NDF neg/p-S6 neg/IGF-IR pos 4 0 100
NDF neg/p-S6 pos/IGF-IR pos 4 0 100
NDF pos/p-S6 pos/IGF-IR neg 7 100 0
NDF pos/p-S6 neg/IGF-IR pos 16 44 56
NDF pos/p-S6 neg/IGF-IR neg 14 36 64
Total 56 37 63
NDF neg/p-ERK pos/EGFR neg 3 0 100 12.75/NS
NDF neg/p-ERK neg/EGFR neg 4 0 100
NDF neg/p-ERK neg/EGFR pos 10 20 80
NDF neg/p-ERK pos/EGFR pos 6 0 100
NDF pos/p-ERK pos/EGFR neg 5 0 100
NDF pos/p-ERK neg/EGFR pos 13 54 46
NDF pos/p-ERK neg/EGFR neg 6 17 83
NDF pos/p-ERK pos/EGFR pos 18 28 72
Total 65 23 77
Analysis on tissue array samples for which clinical and Herceptest data were available
and who overexpressed ErbB2 at the 3+ level.
Figure 2 Diagnostic protocol for predicting patient response to
combination Herceptin and chemotherapy.
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additional predictive information not available at the level of
the receptor or ligand. Analysis of patients treated with Herceptin
as a single agent therapy would be needed to determine which
of the biomarkers we identified are mediating response to
Herceptin itself vs the other therapies. However, our results are
useful in the design of diagnostic tests for breast cancer patients
undergoing the common Herceptin combination therapies. The
protocol outlined in Figure 2 represents a first attempt at such a
diagnostic test.
ACKNOWLEDGEMENTS
We would like to thank Dr Michael DiGiovanna of Yale University
for helpful discussions.
REFERENCES
Altiok S, Batt D, Altiok N, Papautsky A, Downward J, Roberts TM, Avraham
H (1999) Heregulin induces phosphorylation of BRCA1 through
phosphatidylinositol 3-kinase/AKT in breast cancer cells. J Biol Chem
274(45): 32274–32278
Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov
A, Testa JR (2002) AKT2 is frequently upregulated in ERBB2/neu-
positive breast cancers and may contribute to tumor aggressiveness by
enhancing cell survival. Oncogene 21: 3532–3540
Bacus S, Chin D, Stewart J, Zelnick C, Mahvi D, Gilchrist K (1997) Potential
use of image analysis for the evaluation of cellular predicting factors for
therapeutic response in breast cancers. Anal Quant Cytol Histol 19(4):
316–328
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi
K, Yarden Y, Seger R (2001) Taxol-induced apoptosis depends on MAP
kinase pathways (ERK and p38) and is independent of p53. Oncogene 20:
147–155
Bacus SS, Ruby SG (1993) Application of image analysis to the evaluation
of cellular prognostic factors in breast carcinoma. Pathol Annual 28
(Part 1): 179–204
Baselga J (2002) Combined anti-EGF receptor and anti-ERBB2 receptor
therapy in breast cancer: a promising strategy ready for clinical testing.
Annu Oncol 13: 8–9
Camirand A, Lu Y, Pollak M (2002) Co-targeting ERBB2/ErbB2 and insulin-
like growth factor-1 receptors causes synergistic inhibition of growth in
ERBB2-overexpressing breast cancer cells. Med Sci Monit Dec 8(12):
BR521–BR526
Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible
Akt activity promotes resistance to chemotherapy, trastuzumab, or
tamoxifen in breast cancer cells. Mol Cancer Ther 1(9): 707–717
Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B,
Steenbergh PH, Sussenbach JS (1997) Mitogenic signaling of insulin-like
growth factor I in MCF-7 human breast cancer cells requires
phosphatidylinositol 3-kinase and is independent of mitogen-activated
protein kinase. J Biol Chem 272(49): 31163–31171
Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A (2001) Cell
communication networks: epidermal growth factor receptor transactiva-
tion as the paradigm for interreceptor signal transmission. Oncogene
20(13): 1594–1600
Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo
D, Brennan MF, Lewis JJ, Cordon-Cardo C (2001) Validation of tissue
microarrays for immunohistochemical profiling of cancer specimens
using the example of human fibroblastic tumors. Am J Pathol 158(4):
1245–1251
Hortobagyi GN (2001) Overview of treatment results with trastuzumab
(Herceptin) in metastatic breast cancer. Semin Oncol 6(Suppl 18): 43–47
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ,
Seger R, Hynes NE, Yarden Y (1996) ErbB2 is a common auxiliary
subunit of NDF and EGF receptors: implications for breast cancer. EMBO
J 15(2): 254–264
Liu W, Li J, Roth RA (1999) Heregulin regulation of Akt/protein kinase B in
breast cancer cells. Biochem Biophys Res Comm 261: 897–903
Lu Y, Zi W, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth
factor-I receptor signaling and resistance to Trastuzumab (Herceptin).
J Natl Cancer Inst 93(24): 1852
Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-
targeted anticancer therapeutics is influenced by the availability of
epidermal growth factor-related peptides. Cancer Res 62: 3151–3158
Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J, DiAugustine RP,
Barrett JC, Afshari CA, Dunn SE (2002) Insulin-like growth factor-1
inscribes a gene expression profile for angiogenic factors and cancer
progression in breast epithelial cells. Neoplasia 4(3): 204–217
Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y (1993) Cell-type
specific interaction of Neu differentiation factor (NDF/heregulin) with
Neu/ERBB2 suggests complex ligand–receptor relationships. EMBO J
Mar 12(3): 961–971
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y (1996) Neu
differentiation factor/neuregulin isoforms activate distinct receptor
combinations. J Biol Chem 271(32): 19029–19032
Thor AD, Liu S, Edgerton S, Moore II D, Kasowitz KM, Benz CC, Stern DF,
DiGiovanna MP (2000) Activation (tyrosine phosphorylation) of ErbB-2
(HER-2/neu): a study of incidence and correlation with outcome in
breast cancer. J Clin Oncol 18(18): 3230–3239
Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu
N, Yayon A, Wen D, Yarden YJ (1994) Bivalence of EGF-like ligands
drives the ErbB signaling network. J Biol Chem 269(40): 25226–25233
Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood
KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine
kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream
Erk1/2 and AKT pathways. Oncogene 21(41): 6255–6263
Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S,
Miller S, Huang L, Hung MC (2000) The ets protein PEA3 suppresses
ERBB2/neu overexpression and inhibits tumorigenesis. Nat Med 6:
189–195
Yakes FM, Chinratanalab W, Ritter CA, King W, Seeling S, Arteaga CL
(2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase
and Akt is required for antibody-mediated effects on p27, cyclin D1, and
antitumor action. Cancer Res 62(14): 4132–4141
Ye D, Mendelsohn J, Fan Z (1999) Augmentation of a humanized anti-
ERBB2mAb 4D5 induced growth inhibition by a human-mouse chimeric
anti-EGF receptor mAb C225. Oncogene 18(3): 731–738
Biomarkers for targeted therapeutics
BL Smith et al
1194
British Journal of Cancer (2004) 91(6), 1190–1194 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s